Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      TERMINATED
      (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
      Description

      This is a Phase 1/2, open-label, first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of BLU-701 as monotherapy or in combination with either osimertinib or platinum-based chemotherapy in patients with EGFRm NSCLC.

      Conditions
      Lung NeoplasmCarcinoma, Non-Small-Cell LungRespiratory Tract NeoplasmsNeoplasmsNeoplasms by SiteLung DiseasesRespiratory Tract DiseasesCarcinoma, BronchogenicBronchial NeoplasmsAdenocarcinomaCarcinomaNeoplasms by Histologic TypeNeoplasms, Nerve TissueEGFR C797SEGFR C797AEGFR L858REGFR Exon 19 DeletionEGFR Gene MutationEGF-R Positive Non-Small Cell Lung CancerEGFR Mutation Resulting in Tyrosine Kinase Inhibitor ResistanceEGFR Activating MutationThoracic NeoplasmsAntineoplastic AgentsProtein Kinase InhibitorsEGFR C797GEGFR C797XNon Small Cell Lung Cancer
      Talk to us
      TERMINATED
      (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
      Description

      This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-945, a selective EGFR inhibitor, as monotherapy or in combination with osimertinib.

      Conditions
      Lung NeoplasmsCarcinoma, Non-Small-Cell LungRespiratory Tract NeoplasmsNeoplasmsNeoplasms by SiteLung DiseasesRespiratory Tract DiseaseCarcinoma, BronchogenicBronchial NeoplasmsAdenocarcinomaCarcinomaNeoplasms by Histologic TypeNeoplasms, Nerve TissueEGFR T790MEGFR C797SEGFR L858REGFR Gene MutationEGF-R Positive Non-Small Cell Lung CancerEGFR Exon 19 DeletionEGFR Mutation Resulting in Tyrosine Kinase Inhibitor ResistanceEGFR Activating MutationProtein Kinase InhibitorsAntineoplastic AgentsThoracic Neoplasms
      Talk to us